Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Retinoblastoma may occur with symptoms including white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.
The retinoblastoma pipeline drugs market research report provides an analysis of the retinoblastoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases covering the product development milestones. Additionally, the report provides an overview of key players involved in therapeutic development for retinoblastoma and features dormant and discontinued projects.
Retinoblastoma Pipeline Drugs Market Segmentation by Targets
Some of the targets of the retinoblastoma pipeline drugs market are E3 Ubiquitin Protein Ligase Mdm2, Cells Expressing Anthrax Toxin Receptor 1, Cells Expressing Ganglioside GD2, Cellular Tumor Antigen p53, and DNA Topoisomerase I among others.
Retinoblastoma Pipeline Drugs Market Analysis, by Key Targets
For more insights on key targets, download a free report sample
Retinoblastoma Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action of the retinoblastoma pipeline drugs market are E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, Cellular Tumor Antigen p53 Activator, Cytotoxic To Cells Expressing Anthrax Toxin Receptor 1, Cytotoxic To Cells Expressing Ganglioside GD2 and DNA Topoisomerase I Inhibitor among others.
Retinoblastoma Pipeline Drugs Market Analysis, by Key Mechanisms of Action
For more insights on key mechanisms of action, download a free report sample
Retinoblastoma Pipeline Drugs Market Segmentation by Routes of Administration
The routes of administration in the retinoblastoma pipeline drugs market are intravenous, intravitreal, oral, intratumor, and ophthalmic.
Retinoblastoma Pipeline Drugs Market Analysis, by Routes of Administration
For more insights on routes of administration, download a free report sample
Retinoblastoma Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the retinoblastoma pipeline drugs market are small molecule, fusion protein, oncolytic virus, subunit vaccine, and synthetic peptide.
Retinoblastoma Pipeline Drugs Market Analysis, by Molecule Types
For more insights on molecule type, download a free report sample
Competitive Landscape
Some of the key companies in the retinoblastoma pipeline drugs market are Aileron Therapeutics Inc, APEIRON Biologics AG, Ascentage Pharma Group International, Canget BioTekpharma LLC, Chengdu Kanghong Pharmaceuticals Group Co Ltd, and Cothera Bioscience Pty Ltd among others.
Retinoblastoma Pipeline Drugs Market Report Overview
| Key Targets | E3 Ubiquitin Protein Ligase Mdm2, Cells Expressing Anthrax Toxin Receptor 1, Cells Expressing Ganglioside GD2, Cellular Tumor Antigen p53, and DNA Topoisomerase I |
| Key Mechanisms of Action | E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, Cellular Tumor Antigen p53 Activator, Cytotoxic To Cells Expressing Anthrax Toxin Receptor 1, Cytotoxic To Cells Expressing Ganglioside GD2, DNA Topoisomerase I Inhibitor |
| Key Routes of Administration | Intravenous, Intravitreal, Oral, Intratumor, and Ophthalmic |
| Key Molecule Types | Small Molecule, Fusion Protein, Oncolytic Virus, Subunit Vaccine, and Synthetic Peptide |
| Leading Companies | Aileron Therapeutics Inc, APEIRON Biologics AG, Ascentage Pharma Group International, Canget BioTekpharma LLC, Chengdu Kanghong Pharmaceuticals Group Co Ltd, Cothera Bioscience Pty Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
APEIRON Biologics AG
Ascentage Pharma Group International
Canget BioTekpharma LLC
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Cothera Bioscience Pty Ltd
Innovation Pharmaceuticals Inc
Oxular Ltd
PepVax Inc
Seneca Therapeutics Inc
Spectocular LLC
Targeted Therapy Technologies LLC
VCN Biosciences SL
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the retinoblastoma pipeline drugs market?
Some of the targets of the retinoblastoma pipeline drugs market are E3 Ubiquitin Protein Ligase Mdm2, Cells Expressing Anthrax Toxin Receptor 1, Cells Expressing Ganglioside GD2, Cellular Tumor Antigen p53, and DNA Topoisomerase I.
-
What are the mechanisms of action of the retinoblastoma pipeline drugs market?
The key mechanism of action of the retinoblastoma pipeline drugs market are E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, Cellular Tumor Antigen p53 Activator, Cytotoxic To Cells Expressing Anthrax Toxin Receptor 1, Cytotoxic To Cells Expressing Ganglioside GD2, DNA Topoisomerase I Inhibitor.
-
What are the routes of administration in the retinoblastoma pipeline drugs market?
The routes of administration in the retinoblastoma pipeline drugs market are intravenous, intravitreal, oral, intratumor, and ophthalmic
-
What are the molecule types in the retinoblastoma pipeline drugs market?
The molecule types in the retinoblastoma pipeline drugs market small molecule, fusion protein, oncolytic virus, subunit vaccine, and synthetic peptide.
-
Which are the leading companies in the retinoblastoma pipeline drugs market?
Some of the leading companies in the retinoblastoma pipeline drugs market are Aileron Therapeutics Inc, APEIRON Biologics AG, Ascentage Pharma Group International, Canget BioTekpharma LLC, Chengdu Kanghong Pharmaceuticals Group Co Ltd, Cothera Bioscience Pty Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Oncology reports



